113272-40-5

Upstream product

• 92-54-6 4-phenyl-1-piperazine 
• 79-08-3 bromoacetic acid 

Downstream Products

• 99024-81-4 methyl 7-methoxy-3-oxo-4-[2-oxo-2-(4-phenylpiperazin-1-yl)-ethyl]-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate 
• 1610999-44-4 1-{2-[3-(benzyloxy)phenoxy]ethyl}-4-phenylpiperazine hydrochloride 
• 1610999-45-5 3-[2-(4-phenylpiperazin-1-yl)ethoxy]phenol hydrochloride 
• 1611527-02-6 1-{2-[3-(benzyloxy)phenoxy]ethyl}-4-phenylpiperazine 
• 1611527-03-7 3-[2-(4-phenylpiperazin-1-yl)ethoxy]phenol 
• 99013-72-6 methyl trans-3-hydroxy-7-methoxy-4-<2-oxo-2-(4-phenyl-1-piperazinyl)ethyl>-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate 
• 99013-72-6 methyl cis-3-hydroxy-7-methoxy-4-<2-oxo-2-(4-phenyl-1-piperazinyl)ethyl>-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate 
• 113272-91-6 methyl 5-(4-phenyl-1-piperazinyl)-2-(6-methoxy-1,4-benzoxathian-3-yl)pentanoate 
• 99014-08-1 methyl cis-3-hydroxy-7-methoxy-4-<2-(4-phenyl-1-piperazinyl)ethyl>-3,4-dihydro-2H-1,5-benzoxathiepin-4-carboxylate 

Relevant academic research and scientific papers

Synthesis, molecular docking and biological evaluation of coumarin derivatives containing piperazine skeleton as potential antibacterial agents

A series of 4-hydroxycoumarin derivatives were designed and synthesized in order to find some more potent antibacterial drugs. Their antibacterial activities against Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis and Staphylococcus aureus were tested. These compounds showed good antibacterial activities against Gram-positive strains. Compound 4g represented the most potent antibacterial activity against Bacillus subtilis and S. aureus with MIC of 0.236, 0.355 μg/mL, respectively. What's more, it showed the most potent activity against SaFabI with IC50 of 0.57 μM. Molecular docking of 4g into S. aureus Enoyl-ACP-reductase active site were performed to determine the probable binding mode, while the QSAR model was built to check the previous work as well as to introduce new directions.

Design, synthesis, and biological evaluation of chrysin derivatives as potential FabH inhibitors

New series of chrysin derivatives (4a–4t) were designed and synthesized by introducing different substituted piperazines at C-7 position. Their inhibitory effects on FabH were evaluated using two Gram-negative bacterial strains, Escherichia coli and Pseudomonas aeruginosa, and two Gram-positive bacterial strains, Bacillus subtilis and Staphylococcus aureus. To our delight, most of these compounds exhibited a dramatic increase in inhibitory potency, compared with the control positive drugs. Among them, compound 4s exhibited the most potent inhibitory activity with IC50 values of 5.78?±?0.24?μm inhibiting E.?coli FabH and potent antibacterial activity against S.?aureus and E.?coli with MIC of 1.25?±?0.01, 1.15?±?0.12?μg/mL, respectively, comparing to the control positive drugs penicillin G (7.56?±?0.30?μm). Docking simulation was performed to position compound 4s into the FabH active site, and the result showed that compound 4s could bind well with the FabH as potent FabH inhibitor.